Karin Brecht

1.1k total citations
25 papers, 844 citations indexed

About

Karin Brecht is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Karin Brecht has authored 25 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 6 papers in Cardiology and Cardiovascular Medicine and 5 papers in Oncology. Recurrent topics in Karin Brecht's work include Antiplatelet Therapy and Cardiovascular Diseases (4 papers), Drug Transport and Resistance Mechanisms (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Karin Brecht is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (4 papers), Drug Transport and Resistance Mechanisms (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Karin Brecht collaborates with scholars based in Switzerland, Austria and Germany. Karin Brecht's co-authors include Stephan Krähenbühl, Anja Zahno, Michael Török, K. Waldhauser, Stephan Krähenbühl, Priska Kaufmann, Peter W. Lindinger, Peter Mullen, Daniel Konrad and Ferenc Folláth and has published in prestigious journals such as Oncogene, Free Radical Biology and Medicine and International Journal of Molecular Sciences.

In The Last Decade

Karin Brecht

24 papers receiving 815 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karin Brecht Switzerland 15 399 200 159 135 93 25 844
Dagmara Mohuczy United States 12 303 0.8× 149 0.7× 159 1.0× 203 1.5× 125 1.3× 17 913
Anja Zahno Switzerland 6 281 0.7× 130 0.7× 103 0.6× 80 0.6× 68 0.7× 8 514
Steven S. Mundt United States 15 375 0.9× 398 2.0× 113 0.7× 105 0.8× 61 0.7× 23 1.4k
Kazunori Fujimoto Japan 13 306 0.8× 109 0.5× 296 1.9× 161 1.2× 82 0.9× 27 820
Si Gao China 15 536 1.3× 112 0.6× 163 1.0× 104 0.8× 112 1.2× 23 1.1k
Clay T. Cramer United States 14 436 1.1× 330 1.6× 55 0.3× 119 0.9× 141 1.5× 31 1.1k
Jitske de Vries-van der Weij Netherlands 10 326 0.8× 348 1.7× 104 0.7× 56 0.4× 131 1.4× 12 1.0k
Jan Jaap van Lier United States 18 318 0.8× 149 0.7× 162 1.0× 130 1.0× 123 1.3× 38 1.0k
Honghong Liu China 18 464 1.2× 119 0.6× 77 0.5× 230 1.7× 91 1.0× 60 964
Linda K. Buckett United Kingdom 12 421 1.1× 414 2.1× 84 0.5× 47 0.3× 96 1.0× 19 1.1k

Countries citing papers authored by Karin Brecht

Since Specialization
Citations

This map shows the geographic impact of Karin Brecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Brecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Brecht more than expected).

Fields of papers citing papers by Karin Brecht

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Brecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Brecht. The network helps show where Karin Brecht may publish in the future.

Co-authorship network of co-authors of Karin Brecht

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Brecht. A scholar is included among the top collaborators of Karin Brecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Brecht. Karin Brecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brecht, Karin, et al.. (2025). Exploring the main source of coproporphyrins: Observations on transport in red blood cells. Drug Metabolism and Disposition. 53(7). 100108–100108.
2.
Brecht, Karin, et al.. (2024). Humanization of SLCO2B1 in Rats Increases rCYP3A1 Protein Expression but Not the Metabolism of Erlotinib to OSI-420. Journal of Pharmacology and Experimental Therapeutics. 389(1). 87–95. 3 indexed citations
3.
Grube, Markus, et al.. (2023). Various effects of repeated rifampin dosing on coproporphyrin levels in humans. Clinical and Translational Science. 16(11). 2289–2298. 6 indexed citations
4.
Brecht, Karin, et al.. (2022). Impact of the clinically approved Petasites hybridus extract Ze 339 on intestinal mechanisms involved in the handling of histamine. Biomedicine & Pharmacotherapy. 148. 112698–112698. 4 indexed citations
5.
Brecht, Karin, Philippe Couttet, Franziska Paech, et al.. (2016). Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin. Toxicology in Vitro. 40. 55–65. 17 indexed citations
6.
Bonifacio, Annalisa, Gerda M. Sanvee, Karin Brecht, et al.. (2016). IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes. Archives of Toxicology. 91(5). 2223–2234. 25 indexed citations
7.
Zahno, Anja, et al.. (2013). Hepatocellular toxicity of clopidogrel: Mechanisms and risk factors. Free Radical Biology and Medicine. 65. 208–216. 26 indexed citations
8.
Donzelli, Massimiliano, et al.. (2012). Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: Importance of metabolites. Toxicology. 299(2-3). 139–145. 20 indexed citations
9.
Mullen, Peter, Anja Zahno, Peter W. Lindinger, et al.. (2011). Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1813(12). 2079–2087. 62 indexed citations
10.
Zahno, Anja, Karin Brecht, Michael Bodmer, et al.. (2010). Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrelin vitro. British Journal of Pharmacology. 161(2). 393–404. 44 indexed citations
11.
Zahno, Anja, et al.. (2010). The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochemical Pharmacology. 81(3). 432–441. 97 indexed citations
12.
Mullen, Peter, et al.. (2009). Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochemical Pharmacology. 79(8). 1200–1209. 67 indexed citations
13.
Waldhauser, K., Karin Brecht, Simon Hebeisen, et al.. (2008). Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. British Journal of Pharmacology. 155(4). 585–595. 21 indexed citations
14.
Kaufmann, Priska, Michael Török, Anja Zahno, et al.. (2006). Toxicity of statins on rat skeletal muscle mitochondria. Cellular and Molecular Life Sciences. 63(19-20). 2415–2425. 201 indexed citations
15.
Waldhauser, K., Michael Török, Daniel Konrad, et al.. (2006). Hepatocellular Toxicity and Pharmacological Effect of Amiodarone and Amiodarone Derivatives. Journal of Pharmacology and Experimental Therapeutics. 319(3). 1413–1423. 100 indexed citations
16.
Brecht, Karin, et al.. (2005). Hematopoietic transcription factor GATA-2 promotes upregulation of alpha globin and cell death in FL5.12 cells. APOPTOSIS. 10(5). 1063–1078. 7 indexed citations
17.
18.
Brecht, Karin, Mika Simonen, & J. Heim. (2005). Upregulation of alpha globin promotes apoptotic cell death in the hematopoietic cell line FL5.12. APOPTOSIS. 10(5). 1043–1062. 12 indexed citations
19.
Brachat, Arndt, et al.. (2002). A microarray-based, integrated approach to identify novel regulators of cancer drug response and apoptosis. Oncogene. 21(54). 8361–8371. 29 indexed citations
20.
Yabu, H, et al.. (1969). The response of isolated arteries and veins to potassium, osmolarity and drugs.. PubMed. 23(12). 391–8. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dagmara Mohuczy Breakdown of academic impact, for papers by Anja Zahno Breakdown of academic impact, for papers by Steven S. Mundt Breakdown of academic impact, for papers by Kazunori Fujimoto Breakdown of academic impact, for papers by Si Gao Breakdown of academic impact, for papers by Clay T. Cramer Breakdown of academic impact, for papers by Jitske de Vries-van der Weij Breakdown of academic impact, for papers by Jan Jaap van Lier Breakdown of academic impact, for papers by Honghong Liu Breakdown of academic impact, for papers by Linda K. Buckett
Rankless by CCL
2026